健脾软肝方抗肝纤维化机理的研究
|
摘要
肝纤维化是肝细胞受到炎症刺激及发生坏死时,肝脏内纤维结缔组织异常增生的一种慢性、渐进性的病理过程,是慢性肝病向肝硬化发展的必经环节。有资料表明,肝硬化病人已占我国内科总住院人数的4.3%-14.2%,其病死亡率在消化系统疾病中占居第二位,仅次于恶性肿瘤。肝纤维化是一种慢性、进行性、弥漫性的肝脏病变,各种肝脏病变长期反复发作均可以导致肝纤维化的生成。因此,能否延缓、阻断或逆转肝纤维化的发展,具有重大的研究和应用意义。
健脾软肝方为现代组方,是根据传统中医理论“肝病实脾”的理论并结合科学辩证而生成的。健脾软肝方的组方中包含了太子参、黄芪、白术、土鳖虫、枳壳、甘草、等多种中药,本组方中的各单味药分别具有补脾益气燥湿,和中缓急,扶正化邪、活血化瘀、通络理气,柔肝调肝等作用。虽然健脾软肝方在临床上得到广泛的应用,但对健脾软肝方抗肝纤维化机理的研究相对较少。因此,以此作为本实验的研究基点。
本研究首先通过确定健脾软肝方对四氯化碳大鼠肝纤维化模型的治疗作用,通过测定各药物组的肝指数,用赖氏法检测各组间ALT、AST的水平以及HE染色法评价各药物组和模型组间的肝纤维化程度。随后在同一模型中,检测健脾软肝方对大鼠肝纤维化模型中TGF-β/Smad通路、经典WNT通路和PI3K通路中相关因子的表达影响。在TGF-β/Smad通路的研究中,利用RT-PCR法检测健脾软肝方各剂量组中大鼠TGF-β1基因的表达水平,利用免疫组化法检测健脾软肝方各剂量组对TGF-β受体数目的影响,以及用western blot法检测各实验组中肝组织内SMAD3和SMAD7蛋白的表达。而在经典WNT通路的研究中,以PCR手段检测所有相关基因的表达,包括了WNT-3a蛋白、FRZ1和β-catenin,同时也检测了HNF-4和HNF-6基因的表达水平。在PI3K通路的研究中,主要是利用了RT-PCR法检测了PDGF和PI3K mRNA的表达水平,放免法检测各剂量组中大鼠血清的cAMP水平,并利用western blot法检测TIMP-1和MMP-3蛋白的表达水平。此后,再进一步研究脾脏功能的变化对肝纤维化的影响。利用四氯化碳大鼠肝纤维化脾次切除模型,用流式细胞仪来检测各药物组大鼠全血中CD4和CD8细胞亚群比例的变化,以及免疫扩散法检测大鼠血清中IgG的分泌水平。最后通过体外实验,在测定健脾软肝方在大鼠星状细胞HSC-T6细胞的半数毒性浓度。其TC50为0.128mg/ml,以此为基础分别设定三个剂量,分别是TC500. 1mg/ml, TC10 0.025mg/ml和TC0 0.00625mg/ml为实验药物浓度。用流式细胞仪以观察健脾软肝方对大鼠HSC细胞上TRAIL凋亡受体的影响。
在本研究中,利用大鼠肝纤维化模型和体外HSC-T6星状细胞模型相结合,多种检测手段并从多个方面对健脾软肝方的机制进行阐述。通过四氯化碳大鼠肝纤维化模型确定健脾软肝方对肝纤维化的治疗作用。在实验中发现,与模型组相比,健脾软肝方高剂量110g·kg-1组和中剂量40g·kg-1组均有较好的抗肝纤维化作用。表现在能够明显降低肝纤维化大鼠的肝指数,降低ALT和AST水平并且缓解肝纤维化进程。而低剂量组20g·kg-1组对四氯化碳大鼠肝纤维化的治疗作用相对较弱。
随后利用四氯化碳大鼠肝纤维化模型,从多个肝纤维化细胞／因子通路对健脾软肝方的机制进行研究。发现健脾软肝方对肝纤维化的TGF-β/Smad通路、经典WNT通路和PI3K通路均有调节作用。在TGF-β/Smad通路的研究中发现,健脾软肝方高剂量组、低剂量和中剂量组对肝纤维化大鼠中的TGF-β1的mRNA有明显的抑制作用,而且能显著下调TGF-β受体数目,并且能够上调SMAD3、下调SMAD7蛋白的表达,调节SMAD3/SMAD7比例。模型组中的TGF-β1受体的阳性比例达到了43%,而健脾软肝方高剂量组和中剂量组中均少于10%的阳性率,明显低于模型组。而SMAD3/SMAD7蛋白表达比例在模型组为2.01,而健脾软肝方高剂量组和中剂量组分别1.08、1.32,低剂量组则为1.63,显示低剂量组对调节SMAD蛋白的作用稍弱。在经典WNT通路的相关基因的表达中发现,健脾软肝方各剂量组对WNT-3α的表达均有抑制作用,但主要还是通过上调FRZ受体来达到肝纤维化的作用。同时,健脾软肝方还能直接抑制β-catenin的表达。此外,健脾软肝方高剂量组和中剂量组对HNF-4和HNF-6都具有诱导其表达的作用,与模型组相比,表达明显增强。在肝纤维化PI3K通路的研究中,主要以PDGF、PI3K基因的表达和TIMP-1、MMP-3蛋白的表达为切入点。发现健脾软肝方能够明显抑制PDGF、PI3K基因的转录水平,提高机体cAMP合成水平,并能调节TIMP-1和MMP-3的比例。在模型组中,肝纤维化的cAMP水平为47.69fmol/μl,高剂量组、中剂量组和低剂量组分别为86.57、76.87和69.88fmol/μl。
在本研究中,也结合了中医理论“肝病实脾”,结合了大鼠肝纤维化中脾脏功能的异常是否与肝纤维化的进程相关。初步研究证实,在大鼠的肝纤维化模型中,大鼠的脾脏功能会出现紊乱,主要表现在CD细胞亚群的失调,IgG过度增高。显示在肝纤维化进程中,机体的自身的过度免疫或者脾脏功能的紊乱都对肝纤维化有加重作用。在该研究中,利用了四氯化碳大鼠肝纤维化脾次切除模型作为研究对象。发现在肝纤维化进程中,对大鼠脾脏进行次切除术能够明显降低大鼠过度的自身免疫,并且能够调节CD细胞亚群的比例。而健脾软肝方高剂量组和中剂量组均能有效调节机体的免疫能力,防止机体过度自身免疫所造成的肝损伤。其中模型组中的CD4/CD8仅有0.85,而脾次切除组为2.21,健脾软肝方高剂量组、中剂量组和低剂量组分别为2.36、2.25和1.82。最后在体外HSC-T6细胞系的研究中,利用流式细胞仪发现健脾软肝方在0.1mg/ml对细胞上TRAIL凋亡受体的表达有明显的诱导作用。与正常HSC-T6细胞组TRAIL的阳性率23.88%相比,健脾软肝方0.1mg/ml组与0.025mg/ml组的阳性率分别为39.14%、32.72%,分别升高15.26%和8.84%。
综合上述,健脾软肝方可以通过多种渠道发挥抗肝纤维化的作用。健脾软肝方可以影响多种细胞信号通道的,可以从TGF-β/Smad通路、经典WNT通路和PI3K通路来抑制肝纤维化的进展。同时对机体的免疫功能具有调节作用,可以提高CD4/CD8细胞亚群的比例,并能减弱在肝纤维化过程中机体自身过度的免疫反应对肝脏造成的损伤。同时在凋亡方面,健脾软肝方可以直接上调活化HSC-T6细胞上的TRAIL凋亡受体,使活化的HSC-T6细胞进入程序性死亡阶段而发挥抗肝纤维化的作用。
Hepatic Fibrosis is a chronic disease caused by the injuries of hepatic cells. It will lead to the cirrhosis, and even dead. According to the data from clinical, the percentage of cirrhosis patients in the hospital all over the country is about 14.2%, which the mortality takes the second place in the digestive system diseases. So it is worth to study how to deferred and reverse the development of hepatic fibrosis.
The prescription of Jianpiruangan is a modern prescription according to the tra-ditional Chinese theory of "therapy the hepatic with spleen" combined with the di-fferentiation of symptoms and signs. In this prescription, it contains varies herbs, such as Radix Pseudostellariae, Radix Astragali, Atractylis ovata, tuckahoe, Chinese angelica root. White Paeony Root, Danshen Root, Ground Beeltle, oyster, Pangolin Scales, Bitter Orange, liquorice, hawthorn and so on. Every single herb has its own functions in the anti-hepatic fibrosis. This prescription is well used in the clinical, but the mechanism is seldom described or was studied. So we will take a deep research of this prescription to fine out how this prescription takes effects on the anti-hepatic fi-brosis.
We studied this prescription in vivo an in vitro. In vitro experiments, we confirmed the therapeutic effects of this prescription and found that it could reduce the hepatic index in the hepatic fibrosis rats model induction by carbon tetrachloride, lowered the levels of ALT and AST, relieved the degrees of hepatic fibrosis. And in the next in vitro experiments, we found that this prescription could affect multifold cellular signal tunnels in the hepatic fibrosis. In the research of TGF-β/Smad tunnel, we found that this prescription could reduce the expression level of TGF-βand the numer of the TGF-βreceptors in the cells, and adjusted the proportion of the SMAD3 and SMAD7. In the research of classical WNT tunnel, we found that this prescription took effects on the anti-hepatic fibrosis was to enhanced the expression level of FRZ, but not the expressions level of WNT protein. And this prescription could reduced the expression level ofβ-catenin, but enhanced the expression of HNF-4 and HNF-6. In the research of PI3K tunnel, this prescription coudld reduce the transcription of PDGF and PI3K mRNA, raised the cAMP level in the serum, and adjusted the proportion of TIMMP-1 and MMP-3 proteins. And in the further studies, we found the rats with hepatic fibrosis got the functional turbulence in the immune system, which showed the lower proportion of the CD4/CD8 by the rats hepatic fibrosis model with spleen subordinated Resectionlie. The prescription of Jianpiruangan could reduce the secretion of IgG, and adjusted the proportion of CD subcellulars. At last, in the vivo experimental research, we found that the concentration of this prescription of 0.128mg/ml and TC10 0.025mg/ml, could enhance the number of the TRAIL receptors directly which lead the HSC-T6 cells to the apoptosis.
According to the above studies, we knew that the prescription of Jianpiruangan has a good effect on the anti-hepatic fibrosis. It could affect multifold sides of the development of hepatic fibrosis, such as the cellular tunnel, adjustment the function of immune system and induction the cells to apoptosis.
健脾软肝方为现代组方,是根据传统中医理论“肝病实脾”的理论并结合科学辩证而生成的。健脾软肝方的组方中包含了太子参、黄芪、白术、土鳖虫、枳壳、甘草、等多种中药,本组方中的各单味药分别具有补脾益气燥湿,和中缓急,扶正化邪、活血化瘀、通络理气,柔肝调肝等作用。虽然健脾软肝方在临床上得到广泛的应用,但对健脾软肝方抗肝纤维化机理的研究相对较少。因此,以此作为本实验的研究基点。
本研究首先通过确定健脾软肝方对四氯化碳大鼠肝纤维化模型的治疗作用,通过测定各药物组的肝指数,用赖氏法检测各组间ALT、AST的水平以及HE染色法评价各药物组和模型组间的肝纤维化程度。随后在同一模型中,检测健脾软肝方对大鼠肝纤维化模型中TGF-β/Smad通路、经典WNT通路和PI3K通路中相关因子的表达影响。在TGF-β/Smad通路的研究中,利用RT-PCR法检测健脾软肝方各剂量组中大鼠TGF-β1基因的表达水平,利用免疫组化法检测健脾软肝方各剂量组对TGF-β受体数目的影响,以及用western blot法检测各实验组中肝组织内SMAD3和SMAD7蛋白的表达。而在经典WNT通路的研究中,以PCR手段检测所有相关基因的表达,包括了WNT-3a蛋白、FRZ1和β-catenin,同时也检测了HNF-4和HNF-6基因的表达水平。在PI3K通路的研究中,主要是利用了RT-PCR法检测了PDGF和PI3K mRNA的表达水平,放免法检测各剂量组中大鼠血清的cAMP水平,并利用western blot法检测TIMP-1和MMP-3蛋白的表达水平。此后,再进一步研究脾脏功能的变化对肝纤维化的影响。利用四氯化碳大鼠肝纤维化脾次切除模型,用流式细胞仪来检测各药物组大鼠全血中CD4和CD8细胞亚群比例的变化,以及免疫扩散法检测大鼠血清中IgG的分泌水平。最后通过体外实验,在测定健脾软肝方在大鼠星状细胞HSC-T6细胞的半数毒性浓度。其TC50为0.128mg/ml,以此为基础分别设定三个剂量,分别是TC500. 1mg/ml, TC10 0.025mg/ml和TC0 0.00625mg/ml为实验药物浓度。用流式细胞仪以观察健脾软肝方对大鼠HSC细胞上TRAIL凋亡受体的影响。
在本研究中,利用大鼠肝纤维化模型和体外HSC-T6星状细胞模型相结合,多种检测手段并从多个方面对健脾软肝方的机制进行阐述。通过四氯化碳大鼠肝纤维化模型确定健脾软肝方对肝纤维化的治疗作用。在实验中发现,与模型组相比,健脾软肝方高剂量110g·kg-1组和中剂量40g·kg-1组均有较好的抗肝纤维化作用。表现在能够明显降低肝纤维化大鼠的肝指数,降低ALT和AST水平并且缓解肝纤维化进程。而低剂量组20g·kg-1组对四氯化碳大鼠肝纤维化的治疗作用相对较弱。
随后利用四氯化碳大鼠肝纤维化模型,从多个肝纤维化细胞／因子通路对健脾软肝方的机制进行研究。发现健脾软肝方对肝纤维化的TGF-β/Smad通路、经典WNT通路和PI3K通路均有调节作用。在TGF-β/Smad通路的研究中发现,健脾软肝方高剂量组、低剂量和中剂量组对肝纤维化大鼠中的TGF-β1的mRNA有明显的抑制作用,而且能显著下调TGF-β受体数目,并且能够上调SMAD3、下调SMAD7蛋白的表达,调节SMAD3/SMAD7比例。模型组中的TGF-β1受体的阳性比例达到了43%,而健脾软肝方高剂量组和中剂量组中均少于10%的阳性率,明显低于模型组。而SMAD3/SMAD7蛋白表达比例在模型组为2.01,而健脾软肝方高剂量组和中剂量组分别1.08、1.32,低剂量组则为1.63,显示低剂量组对调节SMAD蛋白的作用稍弱。在经典WNT通路的相关基因的表达中发现,健脾软肝方各剂量组对WNT-3α的表达均有抑制作用,但主要还是通过上调FRZ受体来达到肝纤维化的作用。同时,健脾软肝方还能直接抑制β-catenin的表达。此外,健脾软肝方高剂量组和中剂量组对HNF-4和HNF-6都具有诱导其表达的作用,与模型组相比,表达明显增强。在肝纤维化PI3K通路的研究中,主要以PDGF、PI3K基因的表达和TIMP-1、MMP-3蛋白的表达为切入点。发现健脾软肝方能够明显抑制PDGF、PI3K基因的转录水平,提高机体cAMP合成水平,并能调节TIMP-1和MMP-3的比例。在模型组中,肝纤维化的cAMP水平为47.69fmol/μl,高剂量组、中剂量组和低剂量组分别为86.57、76.87和69.88fmol/μl。
在本研究中,也结合了中医理论“肝病实脾”,结合了大鼠肝纤维化中脾脏功能的异常是否与肝纤维化的进程相关。初步研究证实,在大鼠的肝纤维化模型中,大鼠的脾脏功能会出现紊乱,主要表现在CD细胞亚群的失调,IgG过度增高。显示在肝纤维化进程中,机体的自身的过度免疫或者脾脏功能的紊乱都对肝纤维化有加重作用。在该研究中,利用了四氯化碳大鼠肝纤维化脾次切除模型作为研究对象。发现在肝纤维化进程中,对大鼠脾脏进行次切除术能够明显降低大鼠过度的自身免疫,并且能够调节CD细胞亚群的比例。而健脾软肝方高剂量组和中剂量组均能有效调节机体的免疫能力,防止机体过度自身免疫所造成的肝损伤。其中模型组中的CD4/CD8仅有0.85,而脾次切除组为2.21,健脾软肝方高剂量组、中剂量组和低剂量组分别为2.36、2.25和1.82。最后在体外HSC-T6细胞系的研究中,利用流式细胞仪发现健脾软肝方在0.1mg/ml对细胞上TRAIL凋亡受体的表达有明显的诱导作用。与正常HSC-T6细胞组TRAIL的阳性率23.88%相比,健脾软肝方0.1mg/ml组与0.025mg/ml组的阳性率分别为39.14%、32.72%,分别升高15.26%和8.84%。
综合上述,健脾软肝方可以通过多种渠道发挥抗肝纤维化的作用。健脾软肝方可以影响多种细胞信号通道的,可以从TGF-β/Smad通路、经典WNT通路和PI3K通路来抑制肝纤维化的进展。同时对机体的免疫功能具有调节作用,可以提高CD4/CD8细胞亚群的比例,并能减弱在肝纤维化过程中机体自身过度的免疫反应对肝脏造成的损伤。同时在凋亡方面,健脾软肝方可以直接上调活化HSC-T6细胞上的TRAIL凋亡受体,使活化的HSC-T6细胞进入程序性死亡阶段而发挥抗肝纤维化的作用。
Hepatic Fibrosis is a chronic disease caused by the injuries of hepatic cells. It will lead to the cirrhosis, and even dead. According to the data from clinical, the percentage of cirrhosis patients in the hospital all over the country is about 14.2%, which the mortality takes the second place in the digestive system diseases. So it is worth to study how to deferred and reverse the development of hepatic fibrosis.
The prescription of Jianpiruangan is a modern prescription according to the tra-ditional Chinese theory of "therapy the hepatic with spleen" combined with the di-fferentiation of symptoms and signs. In this prescription, it contains varies herbs, such as Radix Pseudostellariae, Radix Astragali, Atractylis ovata, tuckahoe, Chinese angelica root. White Paeony Root, Danshen Root, Ground Beeltle, oyster, Pangolin Scales, Bitter Orange, liquorice, hawthorn and so on. Every single herb has its own functions in the anti-hepatic fibrosis. This prescription is well used in the clinical, but the mechanism is seldom described or was studied. So we will take a deep research of this prescription to fine out how this prescription takes effects on the anti-hepatic fi-brosis.
We studied this prescription in vivo an in vitro. In vitro experiments, we confirmed the therapeutic effects of this prescription and found that it could reduce the hepatic index in the hepatic fibrosis rats model induction by carbon tetrachloride, lowered the levels of ALT and AST, relieved the degrees of hepatic fibrosis. And in the next in vitro experiments, we found that this prescription could affect multifold cellular signal tunnels in the hepatic fibrosis. In the research of TGF-β/Smad tunnel, we found that this prescription could reduce the expression level of TGF-βand the numer of the TGF-βreceptors in the cells, and adjusted the proportion of the SMAD3 and SMAD7. In the research of classical WNT tunnel, we found that this prescription took effects on the anti-hepatic fibrosis was to enhanced the expression level of FRZ, but not the expressions level of WNT protein. And this prescription could reduced the expression level ofβ-catenin, but enhanced the expression of HNF-4 and HNF-6. In the research of PI3K tunnel, this prescription coudld reduce the transcription of PDGF and PI3K mRNA, raised the cAMP level in the serum, and adjusted the proportion of TIMMP-1 and MMP-3 proteins. And in the further studies, we found the rats with hepatic fibrosis got the functional turbulence in the immune system, which showed the lower proportion of the CD4/CD8 by the rats hepatic fibrosis model with spleen subordinated Resectionlie. The prescription of Jianpiruangan could reduce the secretion of IgG, and adjusted the proportion of CD subcellulars. At last, in the vivo experimental research, we found that the concentration of this prescription of 0.128mg/ml and TC10 0.025mg/ml, could enhance the number of the TRAIL receptors directly which lead the HSC-T6 cells to the apoptosis.
According to the above studies, we knew that the prescription of Jianpiruangan has a good effect on the anti-hepatic fibrosis. It could affect multifold sides of the development of hepatic fibrosis, such as the cellular tunnel, adjustment the function of immune system and induction the cells to apoptosis.
引文
[1]Friedman S L. Mac the knits Macrophages-the double-edged sword of hepatic fibrosis[J]. J Clin Invest,2005,115(1):29-32
[2]Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int 2006; 26:8-22
[3]Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol,2008; 214:199-210
[4]Shek F W, Benyon R C, How can transforming growth factor betbe targeted usefully to combat liver fibrosis[J] Eur J Gastroenterol Hepatol,2004, 16:123-6.
[5]Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002; 2:46-53
[6]Isono M, Soda M, lnoue A, et al. Reverse transformation of hepatic myo-fibroblast-like cells by TGFbetal/LAP. Bioehem Biophys Res Commun 2003,311:959-965
[7]Gressner OA,Rizk MS, Kovalenko E, et al. Changing the pathogenetic roadmap of liver fibrosis? Where did it start; where will it go? J Gastroenterol Hepatol 2008; 23:1024-1035
[8]Roberts AB, RUSSO A, Felici A, Flanders KC. Smad3:a key player in pathogenetic mechanisms dependent on TGF—beta. Ann NY Acad Sci 2003; 995:1-10
[9]Cutroneo KR. TGF-beta. induced fibrosis and SMAD signaling:oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring. Wound Repair Regen 2007; 15 (1):S54-S60
[10]Hemmann S, Graf I, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis—a systematic review with special emphasis on anti —fibrotic strtegies. J Hepatol 2007,46:955-975
[11]Brew K, N agase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 2010; 1803:55-71
[12]Pan CH, kn CH, Lin cS. Interplay of angiotensin Ⅱ and angiotensin(1 —7) in the regulation of matrix metalloproteinases of human cardiocytes. Exp Physiol 2008; 93:599-612
[13]Liu J, Gong H, Zhang T, Wang Y. Effect of angiotensinIIand angiotensin Ⅱ type 1 receptor antagonist on the proliferatiOn, contraction and collagen synthesis in rat hepatic stellate cells. Chin Med J, (Engl)2008; 121:161-165
[14]Seifert RA, Hart CE, Phillips PE, et al. Two different subunits Associated to create insoform-specific platelet——derived growth Factor receptors. J Biol Chem,1989,264:8771
[15]Kelly JD, Haldeman BA, Grant FJ, et al. Platelet—derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersub—unit trans-phosphorylation. J Biol Chem,1991,266:8987
[16]Breitkopfk, Roeyen C, Sawitza I, et al. Expression patterns of PDGF-A,-B,-C and-D and the PDGF-receptors alpha and beta in activated rat hepatic stellate cell (HSC). Cytokine.2005 Sep7:31(5): 349-57
[17]Borkham Kamphorst E, Stoll D, Gressner AM,et al. Inhibitory effect of soluble PDGF beta receptor in culture activated hepatic stellate cells. Biochem Biophys Res Commun,2004,317:451-462
[18]Borkham Kamphorst E, Herrmann J, Stoll D, et al. Dominant negative soluble PDGF beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest,2004,84; 766-777
[19]Di Sario A, Bendia E, Svegliati Baroni G, et al. Rearrangement of the cytoskeletal network induced by platelet derived growth factor in rat hepatic stellate cells:role of different intracellular signaling pathways. J Hepatol,2002,36:179-190
[20]Abou Shady M, Friess H, Zimmermann A, et. Connective tissue growth factor in human liver cirrhosis [J]. Liver,2000,2(4):296-304
[21]Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol,2001,13:211-217
[22]AldegulerX, Debonera F. Shaked A. et al. Hepatology:200235;40-48
【23]徐燕,杜文军,秦来英,等.白细胞介素17在乙肝肝纤维化中的表达及意义[J].细胞与分子免疫学杂志,2009,25(2)：133—135.
[24]Zheng W D, Zhang L J, Shi M N, et al. Expression of matrix metal. loproteinase-2 and tissue inhibitor of metal loproteinase—1 in hepatic stellate ceils during rat hepatic fibrosis and its intervention by IL —10[J]. World J Gaatroenterol,2005,11(12):1753-1758
[25]Tomita K, Tamiya G, Ando S, et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non—ahoholic steatohepatitis in mice[J]. Gut, 2006,55:415-24.
[26]Migita K, Maeda Y, Abiru S, et al. Immunosuppressant FKS06 inhibits matrix metalloproteinase-9 induction in TNF-alpha--stimulated human hepatic stellate cells, [J]Sci,2006,78(21):2510-2515
[27]Wan R, wu Y L, Qiao M M, et al. Effect of insulin—like growth factor-1 on hepatic fibrosis in rats[J].% rfd Chin J Digestol, 2005.13(2):211—3.
[28]刘立新,张骞骞,韩德五,等.IGFBP2、IGFBP6在TGF-β1活化的肝星状细胞中表达[J].中国病理生理杂志,2008,24(12)；2481—2483
[29]Vera M, Sobrevals L, Zaratiegui M. et al. Liver transduction with a simian virus 40 vector encoding insulin—like growth factor I reduces hepatic damage and the development of liver cirrhosis [J]. Gene Ther,2007, 14(3):203-10
[30]Tang X, Yang J.Ⅱ J. Sensitization of human hepatic stellate cells to tumor necrosis factor—related apoptosis—inducing ligand— inducedapoptosis by leflunomide[J]. Biol P Bul,2009,32(6):963-967
[31]Son G, Iinmro Y, Seki E, et al. Selective inactivation of NF-kappaB in the liver using NF—kappaB decoy suppresses CC14—induced liver injury and fibrosis[J]. Am J Physiol Gastrointest Liver Physiol, 2007,293(3):G631-9.
[32]Bethanis S K, Theocharis S E. Leptin in the field of hepatic fibro— sis:pivotal or an incidental player, [J]Dig Dis Sei,2006,51 (10):1685-1696.
[33]Honda H, Ikejima K, Yoshikawa M, et al. Leptin is required for fibrogenic responses induced by thioacetamide in the routine liver [J]. Hepatology,2002,36(1):12-21
[34]Nong B, Luo H S, Liang Z W, et al. Relationship between leptin and liver fibrogenesis of rats[J]. Acta Med Sin,2006,19(3):386-388.
[35]Wang J, Leclercq I, Brymora JM, et al. kupffer cells mediate leptin—induced liver fibrosis[J]. Gastroenterology,2009,137(2):713-723.
[36]sj HF.Li J, Lin X, et al. Suppressive effects of leflunomide on leptin-induced collagen I production involved in hepatic stellate cell proliferation[J]. Exp Biol Med,2007,232(3):427-436.
[37]J, Si HF, Lin X, et al. Suppressive effects of leflunomide on leptin--induced TIMP-1 production involves on hepatic stellate cell proliferation and apoptosis[J]. Eur JPharmacol,2008,580(1-2): 63-69.
[38]Radaeva S, Jaruga B, Kim WH, et al. Interferon gamma inhibits interferon alpha signalling in hepatic cells:evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitic C. Biochem J,2004,379:199-208.
[39]Rockey DC, Maher JJ, Jarnagin WR, et. Inhibition of rat hepatic lipocyte activation ineulture by interferon—…. Hepatology,1992, 16(3):776-778.
[40]Tsushima H, Kawata S, Tamara S, et. Reduced plasma transforming growth faetor-betal levels in patients with chronic hepatitis C after in terferon—alpha therapy:Association with regression of hepatic fibros[J]. J Hepatol,1999,30(1):1-7.
[41]Benyon RC, Iredale JP. Is liver fibrosis reversible, Gut 2000:46:443-446
[42]Pinzani M, Marra F, Carloni V. Signal transduction in hepatic stellate cells. Liver 1998:18:2-13
【43]陈平圣,翟为溶,张月娥,张锦生.缺氧对肝星状细胞产生胶原及胶原降解酶影响。世界华人消化杂志2000;8：586-587
[44]白文元,姚希贤,冯丽英.肝纤维化的研究现状.世界华人消化杂志2000;8：1267-1268
[45]Kim KY, Rhim TY, Choi IC, Kim SS. N-Acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity. J Biol Chem 2001; 276:40591-40598
[46]Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000:275:2247-2250
[47]Svegliati-Baroni G, Ridolfi F, Di Sario Benedetti A, et al. Intracellular signaling pathways involved in acetaldehyde-induced collagen and fibronectin gene expression in human hepatic stellate cells. Hepatology 2001:33:1130-1140
[48]Schnabl B, Kweon Y0, Frederick JP, et al. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 2001:34:89-100
[49]甘新宇,蒋明德PDGF与HSC中信号传导关系的研究进展.西南国防医药2000；10：246
[50]Robino G, Parola M, Marra F, Caligiuri A, et al. Interaction between 4-hydroxy-2,3-alkenals and the platelet derived growth factor-beta receptor. Reduced tyrosine phosphorylation and downstream signaling in hepatic stellate cells. J Biol Chem 2000;275:40561-40567
[51]Shimohashi N, Nakamuta M, Uchimura K, et al.. Selenoorganic compound, ebselen, inhibits nitric oxide and tumor necrosis factor-alpha production by the modulation of jun-N-terminal kinase and the NF-kappab signaling pathway in rat Kupffer cells. J Cell Biochem 2000;78:595-606
[52]DerynckR, ZhangYE. Smad dependent and Smad-independent pathways In TGF-Beta familysignaling [J]. Nature,2003,425(6958):577-584
[53]ShiY, MassagueJ. Mechanisms ofTGF-beta signaling from cell membranetothenucleus[J]. Cell,2003,113:685-700
[54]杨小艳,杨勇,郑勇,等.外源Smad7转染肝星状细胞及对转化生长因子B1和Ⅰ、Ⅲ型胶原mRNA表达的影响[J].中国组织工程研究与临床康复,2009,13(50)：9887-9891
[55]NagarajanRP, ChenF, LiW, et al. Repression of transforming growth factor beta mediated transcription by nuclear factor kappaB. [J]. Biochem J,2000,348:591-596.
[56]Bitzer Mvon, LiangD, etal. A mechanism of suppression of TGFbeta/SMAD signaling by NF-kappaB/Re1A. [J].EP Genes Dev,2000,14:872-971.
[57]袁丽萍,陈飞虎,鹿玲,等.鬼针草总黄酮对肝纤维化大鼠肝星状细胞TGF-β1信号传导通路的影响[J].中国药理学通报,2009,25(12)：1655-1659
[58]S Dooley, J Hamzavi, K Breitkopf, et al. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. [J] Gastroenterology, 2003,125(1):178-191
[59]Cano E, Mahadevan LC. Parallel signal processing among mammalian MAPKs. TIBS 1995;20:117-122
[60]Seger R, Krebs EG. The MAPK signaling casade. FASEB J 1995:9:726
[61]Shapiro PS, Ahn NG. Feedback regulation of raf-1 andmitogenactivated protein kinase (MAP) kinase kinases 1 and 2 by MAP kinase phosphatase-1 (MKP-1). J Bio Chem 1998:273:1788-1793
[62]Davis RJ. The mitrogen-activated protein kinase signal transduction pathway. J Biol Chem 1993;268:14553-14556
[63]Page G, Guerin S, Grall D, Bonino F, et al. Defective thymocyte maturation in P44 MAP kinase (Erkl) knock out mice. Science 1999;286:1374-1377
[64]New L, Jiang Y, Zhao M, et al. PRAK, a novel protein kinase regulated by the P38 MAP kinase. EMBO J 1998:17:3372-3384
【65】刘景生.细胞信息与调控.第1版.北京：北京医科大学中国协和医科大学联合出版社,1998：272
[66]Tanoue T, Moriguchi T, Nishida E. Molecular cloning and characterization of a novel dual specificity phosphatase, MKP-5. J Biol Chem 1999:274:19949-19956
[67]Friedman SL. The cellular basis of hepatic fibrosis-mechanisms and treatment strategies. N Engl J Med 1993:328:1828-1835
[68]Aronheim A, Engelberg D, Li N, et al. Membrane targeting of the nucleotide exchange factor sos is sufficient for activating the ras signaling pathway. Cell 1994;78:949-961
[69]Rosen LB, Greenberg ME. Stimulation of growth factor receptor singal transduction by activation of voltage-sensitive calcium channels. Proc Natl Acad Sci USA 1996;93:1113-1118
[70]Farnsworth CL, Freshney NW, Rosen LB, Ghosh A, Greenberg ME, Feig LA. Calcium activation of ras mediated by neuronal exchange factor ras-GRF. Nature 1995;376:525-527
[71]Berra E, Diaz-Meco MT, Lozano J, Frutos S, Municio MM, Sanchez P, Sanz L, Moscat J. Evidence for a role of MEK and MAPK during signal transduction by protein kinase C zeta. EMBO J 1995:14:6157-6163
[72]JF, Petersen DR. Involvement of phosphatidy insitol kinase and extracellular_regulated kinase in hepatic stellate cell an tioxidan tresponse and mvofibroblastic transdifferentiation [J]. Arch Biochem Biophys 2006,446:111-118
[73]Zhou Y, Zheng S, Lin J, et al. The interruption of the PDGF and EGF signaling pathways by curcumin stimulates gene expression of PPAR gamma in rat activated hepatic stellate cell invitro[J], Lab Invest, 2007,87(5):488-498
[74]朱婉凌,马希涛,王思勤PI3K、α—SMA蛋白在特发性肺纤维化肺组织的表达及意义,中国实用医刊,2008,35(12)：27-29
[75]JRoberts R, James N, Cosulich S, etal. The role of protein kinase B and mitogen-activated protein kinase in epidermal growth factor and tumor necrosis factor—a mediated rat hepatocyte survival and apoptosis. Hepatoloy,2000,31:420-427
[76]姚鹏,杨晓明,胡大荣,PI3K/AKT途径在HGF介导肝干细胞抗凋亡调控中的作用,中华微生物和免疫学杂志,2005,25(2)；89-93
[77]刘剑毅,李世荣,PI3K/PKB信号通路参与结缔组织生长因子促人增生性瘢痕纤维化,重庆医学,2008,37(9)：920-923
【78]陈勇,PI3K在T淋巴细胞活化与细胞毒效应中的作用,国外医学免疫学分册,2002,25(3);154-155
【79]刘瑾,施珊娜,许淑云,等.PI3K在细胞外基质分泌细胞因子表达中的作用,中华微生物学和免疫学杂志,2009,29(7)：597-601
[80]Rane MJ。Coxon PY, Powell DW, et al. p38 KiFlaae dependent MAPKAPK 2 activation functions as 3 phosph。inOsitide-dependent kinase—2 for Akt in human neutrophils. J Biol Chem,2001.276 (5):3517-3523.
[81]Steelman LS,. Pohnert S [:, Shelton JG,1} 11. JAK/STAT. RM/ MEK/ERK, PI3K/Akt and BCR ABI in cell cycle progression and leukemogenesis. Leukemia,2004,18(2):189 218
[82]Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt(protein kinase B), Science,1999,286(5445):1741-1744.
[83]Guan KI, Figueroa C, Brtva TR. et al. Negative regulation of these serine /threonine kinase 13-Raf by Akt, J Biol Chem,2000,275(35):27354-27359.
[84]何益,熊伍军,刘菲.Wnt信号转导通路与肝纤维化,[J].国际消化病杂志,2008,28(1)：57--59
[85]Veeman MT, Axelrod JD, Moon RT. A second canon:Functions and mechanisms of beta-catenin independent Wnt signaling, [J]. Dev Cell,2003,5(3): 367-77
[86]Jiang F, Parsons CJ, Stefanovie B. Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation, [J]. Hepatol,2006,45(3):401-409.
[87]Colston JT, dela Rosa SD, Koehler M, et al. Wnt-induced secreted protein-1 is a prohypertrophic and profibrotic growth factor[J]. Am J Physiol Heart Cire Physiol,2007,293(3):H1839-1846.
[88]Bayle J, Fitch J, Jacobsen K, et al. Increased expression of Wnt2 and SFRP4 in Tsk mouse skin:role of Wnt signaling inaltered dermal fibrillin deposition and systemic sclerosis[J]. J Invest Dernmtol, 2008,128(4):871-881.
[89]Sato M. Up regulation of the Wnt/beta—catenin pathway induced by transforming growth factor—beta in hypertrophic scars and keloids [J]. Acta Dern Venereol,2006,86(4):300-307.
[90]Zeng G, Awan F, Otruba W, et al. Wnt'er in liver:expression of wnt and frizzled genes in mouse [J]. Hepatology,2007,45 (1):195-204
[91]Wells RG, Fibrogenesis. V. TGF—beta signaling pathways. Am, Phvsiof Gastrointest Liver Phvsiof 2000:279:G845-G850
【92]孙利兵,王尉平,顾振纶,等.Wnt信号转导通路与肝纤维化[J].中国药理学通报,2008,24(7)；861—864
[93]De Bleser PJ Niki T|Xu G|Rogiers V|Geerts A. Localization and cellular sources of activins innormal and fibrotic rat liver. HepatoloRy 199 26: 905-912
[94]Kiyici M, Gurel S, Budak F, et al. Fas antigen(CD95)expression and apoptosis in hepatocytes of patients with chronic viral hepatitis. Eur J 17Gastroenterol Hepa tol,2003,15:1079-1084,
[95]Murota M, Watanabe S, Fujita J, et al. Aberrant cytokeratin expression and hight susceptibility to apoptosis in autoimmune hepatitis, s. Hepatol Res,2003.25:271-280.
[96]Takehara T, Tatsumi T, Suzuki T, et al. Hepatocyte-speciilc disruption of Bcl—XL leads to continuous hepatocyte apoptosis an d liver fibrotic responses Gastroenterology,2004,127:1189-1197.
[97]Fadok VA, de Cathelineau A, DMeke DL, et al. Loss of phospholipid asymmetry and surface exposure of phosphatidylsefine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J Biol Chem,2001,276:1071-1077.
[98]Canbay A, Taimr P, Torok N, et al. Apoptofic body engulfment by a human stelate eel line is profibrogenic. Lab Invest,2003,83:655-663.
[99]Wielockx B, Larmoy K, Shapiro SD, et al. Inhibition of matrix metalloproteinases blocks lethal hepatitis an d apoptosis induced by tumor necrosis factor an d allows safe anti-tumor therapy. Nat Med, 2001,7:1202-1308
[101]陈旭军.肝纤维化动物模型的选择及评价,[J],湖南中医药导报,2002,8(12) 785
【102】曾林,王慧芳,肝纤维化动物模型的研究概况,[J]中国医学杂志,2003,13(2)：124
【103】黄志刚,程为溶,张月娥等,异种动物血清诱导的大鼠肝纤维化模型及其机制,[J]上海医科大学学报,1997,24(5)；351
【104】刘秀英,胡怡秀,胡余明等,大鼠四氯化碳和猪血清肝纤维化模型比较,[J],世界华人消化杂志,200210(8)；975-978
[105]kobayashi S, Seki S, Kawada N, et al. Apotosis of T cells in the hepatic fibrotic tissue of the rat:apossible inducing role of hepatic myofiborblast-like cells [J]. Cell tissue Res,2003,311(3):353-364
[106]Nan JX, Park E, Lee SH, et al. Antifibrotic effect of stephania tetrandra on experimental liver fibrosis induced by bile duct ligation and scission in rats [J], Arch Pharm Res,2000,23(5):501-506
【107】尹珊珊,王宝恩,王泰龄等,胆管阻塞性肝纤维化亚模型的建立与改进,【J】中华肝病杂志,2002,10(5)：385-386
【108】陈秀英,季晖,张奕华,等.一氧化氮供体型齐墩果酸衍生物ZCⅡ2对早期实验性肝纤维化的保护作用,中国临床药理和治疗学,2005；10(11)：1261—1265
[109]Hamada H, Yatsuhashl H, Yano K, et al. Interleukin—10 promoter polymorpbiSInS and liver fibrosis progression in patients with chronic hepatitis C in Japan. J Hepatol.2003; 39(3):457-458
[110]Nelson DR, Tu Z, Soldevila Pico C, et al. Long term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti—inflammatory effect. Hepatology.2003; 38(4):859-868
[111]Barth H, Klein R, Berg PA, et al. Analysis of the effect of IL—10 therapy on immunoregulatory T—cell subsets in patients with chroniC hepatitis C infection. Hepatogastroenterology.2003; 50(49):201-206.
【112】谢娟,张惠娜,黄能慧,李诚秀,秋水仙碱对免疫性肝纤维化的防治作用贵州医药,2002,26(10)：885-887
【113】吕霞,舒建昌,何雅军,秋水仙碱抑制肝星状细胞活化与抗肝纤维化的作用,广东医学,2006,27(12)：1796-1798
[114]Luckey Sw, peterson DR, Activation of kuppfer cells during the course of carbon tetrachloride induced liver injury and fibrosis in mice[J]exp mol pathol,2001,71(3):226-228
【115】陆伦根.肝纤维化的药物治疗.药品评价,2006,3(5)：339-340
【116】江余勤,程五风,李宣海.维生素E与肝纤维化.临床肝胆病杂志,2000,16(1)： 19
[117]Guo JS, Wang JY, Liu WT, et al. Effects of potenlini and IFN-α on mRNA expression of procollagen type Ⅰ, Ⅲ and collagenase in liver and hepatic fibrosis model, Gut,1997,41(13):A178-180
[118]苌新明,常英,干扰素对实验大鼠肝内纤维组织及肝星状细胞的影响,肝脏,2004,9(13)：171-173
[119]Watnabe T, Nioka A, Hozawa S, et al. Dynamic of cell s expressing MMP-2 mR.NA and MTi-MMP mRNA in the recoverv from liver fibrosis in the rat. J Hepatol,2001,35:465-473
[120]BARONI GS, D'AMBROSIO L, CURTO P, et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis[J]. Hepatology,1996,23:1189-1199
[121]ROCKEY DC. Antiftbrotic therapy in chronic liver disease[J]. Clin Gastroenterol Hepatd,2005,3(2):95-100
[122]WENG HL, CAI WM, LIU RH. Animal experiment and clinical study of effect of gamma-interferon on hepatic fibrosis[J]. World J Gastroenterology, 2001,7(1):42-44
[123]WENG H, MERTENS PR, GRESSNER AM, et al. IFN-gamma abrogates profibrogenic TGF-beta signaling in liver by targeting expression of inhibkory and receptor Smads [J]. J Hepatol,2007,46(2):295-303
[124]WANG L, WANG BE, WANG J, et al. Herbal compound 861 regulates mRNA expression of collagen synthesis.2005,12; 144-147
[125]Ruwart MJ, Henley KS. Prostaglandins in liver disease and liver transplantation. Gastroenterol Clin North Am.1996 Jun;25(2):397-407.
[126]Lim DS, lutucuta S, Bachireddy P, et al. Angiotensin Ⅱ blockade reverse mycocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomycopathy, [J] circulation,2001,103(6);789-791
[127]胡咏武,王胜春,李哲,等.丹参酮Ⅱ A对LPs等诱导的肝细胞损伤及枯否细胞释放细胞因子的作用[J].中国药理学通报,2005,21(12)：1482—1486
[128]刘成海,刘平,胡义扬,等.丹酚酸B盐对转化生长因子—β 1刺激肝星状细胞活化与胞内信号转导的作用[J].中华医学杂志,2002,82(18)：1267—1272
[129]赖文芳,吴符火,陈兴明.丹参抗肝纤维化作用机制的研究进展,中国民族民间医药2010,2：31-33
[130]郭伟强,陈曦,曹婷婷等,丹参酮Ⅱ—A对抗炎症因子Ⅱ—10的调节作用时效关系[J].中国药理学通报,2009,25(5)：697—680
【131]王要军,孙自勤,权启镇等.汉房己甲素治疗大鼠实验性肝纤维化的研究.临床肝胆病杂志,1993,9(3)：40—41
[132】王继明,倪世秋.络病用药规律处探.中国中医基础医学杂志,2001,7(3)：56-58
[133]杨文卓,曾民德,范竹萍,等.氧化苦参碱防治二甲基硝胺诱导的大鼠肝纤维化的实验研究[J].中华消化杂志,2003,23(3)：165—168.
[134]余小虎,朱金水,朱祖明,等.氧化苦参碱对肝纤维化大鼠肝组织TGF-β1与TNF-α表达的影响[J].肝脏,2004,9(4)：254—255
[135]谈博,宋健平,张奉学,等.川芎嗪对HSC-T6细胞Smad蛋白细胞内转位的影响[J].中药新药与临床药理,2006,17(5)：320—322.
[136]董玲,孙剑勇,方国汀,等.甘草酸对转化生长因子β刺激肝星状细胞信号传导的作用[J].中华肝脏病杂志,2005,13(11)：828—831.
[137]谢明,廖晓宏,杨元胜,等.姜黄素对肝星状细胞株CTGF表达的影响[J].实用医学杂志,2006,22(15)：1724—172
[138]肖东征,高艽,马宁.水飞蓟磷脂复合物对化学性肝损伤的保护作用[J].中国自然医学杂志,2005,7(3)：205—207
[139]王字,贾继东.水飞蓟的抗肝纤维化作用及其机制[J].中华医学杂志,2005,85(17)：1219—1221
[140]王占海,沈凌鸿,陈向东,等.水飞蓟素对脂多糖大鼠急性肺损伤的拮抗作用[J].中国病理生理学杂志,2007,23(2)：280-283
[141】邢凌翔,贺永文.水飞蓟素对大鼠非酒精性脂脉性肝炎的防治作用及机制[J].胃肠病学和肝病杂志,2007,16(1)：60-62
[142]王宇,贾继东,杨寄华,等.水飞蓟素对实验性肝纤维化大鼠的疗效及其作用机制的研究[J].国外医学.消化系疾病分册,2005,25(4)：256-259
[143]刘平,方步武,刘成,等.转化生长因子β1及虫草多糖对大鼠肝纤维化形成的影响.中华肝脏病杂志1998；6(4)：232
[144]方步武,刘平,刘成,等.虫草多糖抗免疫损伤性大鼠肝纤维化的作用及其机理研究.上海中医药杂志2000；34(9)：37-38
[145]Shimim I. Sho-saiko-to:Japanese herbal medicine for protection nst hepatlcfibrosis and eareinonm. J Gastorenterol Hepatol,2000,15:D84
[146]尤红,王宝恩,王泰龄,等.复方861对肝星状细胞的增殖和凋亡的干预作用.中华肝脏病杂志,2010,8(2)：78—80
[147]王宝恩.肝纤维化及肝硬变的可逆性.中西医结合肝病杂志,2000,(S1)：2241
[148]姜春萌,刘成海,刘成.扶正化瘀胶囊对肝星状细胞激活的干预.中国中西 医结合消化杂志,2003；11(5)：280
[149]蔺武,刘心娟.复方鳖甲软肝片抗肝纤维化疗效的系统评价.胃肠病学和肝病学杂志,2007,16(1)：69—71
[150]宣红萍,孙保木,陶艳艳,等.扶正化瘀方对大鼠脂肪性肝炎与肝纤维化的作用[J].药品评价,2007,4(6)：414-418
[151]张琪,田字彬.小柴胡汤对实验性肝纤维化模型大鼠肝组织中Ⅰ、Ⅲ型胶原表达干预研究[J].山东中医药大学学报,2005,45(4)：316—318
[152]周小舟,周大桥.中药软肝冲剂对肝纤维化大鼠p21细胞周期调控的影响[J].中国中西医结合消化杂志,2003,11(5)：267-269
[153]都广礼,郑洪新,刘学文,等.免疫性肝纤维化大鼠脾脏淋巴细胞产生IL-2和IFN—Y的变化及疏肝利胆方药物血清对其影响[J].中医药学刊,2005,23(1)：75—76
[154]张俊杰,黄亚鹏,李寿生等, 桃核参术汤对大鼠肝纤维化形成过程中Ang Ⅱ 1型受体mRNA表达的影响,世界中西医结合杂志,2010,5(7)；586-587
[155]姜春萌,刘成,刘平.肝纤维化过程中肝星状细胞研究进展[J].中华消化杂志,2000,20(4)：30-32
[156】薛博瑜,清化瘀毒法治疗肝纤维化的体会【J】.江苏中医药,2007,39(5)；63-65
【157]杨培明聂广,重型肝炎的诊断与治疗,中西医结合肝病杂志,1998,8(4)；195-197
【158]齐洪军,胡曼菁,祛瘀化痰汤对肝纤维化大鼠肝组织α-平滑肌肌动蛋白表达、分布的影响的实验研究,青海医药杂志,2004,34(5)：14-17
【159]卢良威,陈群伟,蔡卫民等,肝纤维化大鼠Bcl—2、Bax的表达及活血渗湿方对其的作用,浙江中医学院学报,2003,3(27)；51-53
[160]杨倩,胡冬菊,冯玉彦等,姚希贤教授中西医结合治疗慢性肝炎肝纤维化经验,【J】陕西中医,2007,28(9)：1209—1211
[161】朱建明.“活血软坚合剂”对肝纤维化血清指标的影响.江苏中医药2006;27：27-28
[162]张斌,王灵台,陈建杰,王中华,赵莹.虎杖清肝汤治疗慢性乙型肝炎及对肝纤维化形成的影响.上海中医药大学学报2007：21：37-39
[163]孙劲晖,调肝理脾方治疗酒精性肝纤维化,医药信息,2002,19(2)：45
[164]吴秀美,刘友章,软肝抗纤方治疗肝纤维化41例疗效观察,新中医,2003,35(3)：29-31
[165]李志伟,程良斌,抗纤软肝颗粒对大鼠肝星状细胞增殖的影响,中西医结合肝病杂志,2010,20(2)：95-97
[166]刘益平,软肝抗纤方对肝纤维化实验大鼠TGF-1/Smad信号转导通路的影响,中国医药指南,2010,第8卷,1650-1652
[167]刘天虹,健脾软肝方抗肝纤维化的临床观察,广西中医学院学报,2005,8(2);7
[168]薛霁,郑万平,徐丹,健脾软肝煎治疗乙肝肝纤维化(肝郁脾虚证)30例疗效观察,新中医,2005,37(12)；44-46
[169]陈文慧,唐阁,马洁,福尔肝健脾软肝方及拆方对GEl4肝纤维化大鼠脂质过氧化的影响,云南中医学院学报,2007,30(4)；34-37
[170]陈文慧,魏东,马洁,等,福尔肝健脾软肝方及拆方对GEl4肝纤维化大鼠MMP—2、MMP—9活性及蛋白表达的影响,云南中医学院学报,2007,30(1)；29-32
[171]陈文慧,魏东,唐阁,福尔肝健脾软肝方及拆方对CCI4肝纤维化大鼠肝功能的影响,云南中医学院学报,2006,29(4)；13-16
[172]雷力民,田玉玲,邓洪彪,升肝健脾颗粒对肝纤维化大鼠肝脏细胞因子含量的影响,广西南宁辽宁中医药大学学报,2008,10(10)；153
[2]Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int 2006; 26:8-22
[3]Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol,2008; 214:199-210
[4]Shek F W, Benyon R C, How can transforming growth factor betbe targeted usefully to combat liver fibrosis[J] Eur J Gastroenterol Hepatol,2004, 16:123-6.
[5]Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002; 2:46-53
[6]Isono M, Soda M, lnoue A, et al. Reverse transformation of hepatic myo-fibroblast-like cells by TGFbetal/LAP. Bioehem Biophys Res Commun 2003,311:959-965
[7]Gressner OA,Rizk MS, Kovalenko E, et al. Changing the pathogenetic roadmap of liver fibrosis? Where did it start; where will it go? J Gastroenterol Hepatol 2008; 23:1024-1035
[8]Roberts AB, RUSSO A, Felici A, Flanders KC. Smad3:a key player in pathogenetic mechanisms dependent on TGF—beta. Ann NY Acad Sci 2003; 995:1-10
[9]Cutroneo KR. TGF-beta. induced fibrosis and SMAD signaling:oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring. Wound Repair Regen 2007; 15 (1):S54-S60
[10]Hemmann S, Graf I, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis—a systematic review with special emphasis on anti —fibrotic strtegies. J Hepatol 2007,46:955-975
[11]Brew K, N agase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 2010; 1803:55-71
[12]Pan CH, kn CH, Lin cS. Interplay of angiotensin Ⅱ and angiotensin(1 —7) in the regulation of matrix metalloproteinases of human cardiocytes. Exp Physiol 2008; 93:599-612
[13]Liu J, Gong H, Zhang T, Wang Y. Effect of angiotensinIIand angiotensin Ⅱ type 1 receptor antagonist on the proliferatiOn, contraction and collagen synthesis in rat hepatic stellate cells. Chin Med J, (Engl)2008; 121:161-165
[14]Seifert RA, Hart CE, Phillips PE, et al. Two different subunits Associated to create insoform-specific platelet——derived growth Factor receptors. J Biol Chem,1989,264:8771
[15]Kelly JD, Haldeman BA, Grant FJ, et al. Platelet—derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersub—unit trans-phosphorylation. J Biol Chem,1991,266:8987
[16]Breitkopfk, Roeyen C, Sawitza I, et al. Expression patterns of PDGF-A,-B,-C and-D and the PDGF-receptors alpha and beta in activated rat hepatic stellate cell (HSC). Cytokine.2005 Sep7:31(5): 349-57
[17]Borkham Kamphorst E, Stoll D, Gressner AM,et al. Inhibitory effect of soluble PDGF beta receptor in culture activated hepatic stellate cells. Biochem Biophys Res Commun,2004,317:451-462
[18]Borkham Kamphorst E, Herrmann J, Stoll D, et al. Dominant negative soluble PDGF beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest,2004,84; 766-777
[19]Di Sario A, Bendia E, Svegliati Baroni G, et al. Rearrangement of the cytoskeletal network induced by platelet derived growth factor in rat hepatic stellate cells:role of different intracellular signaling pathways. J Hepatol,2002,36:179-190
[20]Abou Shady M, Friess H, Zimmermann A, et. Connective tissue growth factor in human liver cirrhosis [J]. Liver,2000,2(4):296-304
[21]Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol,2001,13:211-217
[22]AldegulerX, Debonera F. Shaked A. et al. Hepatology:200235;40-48
【23]徐燕,杜文军,秦来英,等.白细胞介素17在乙肝肝纤维化中的表达及意义[J].细胞与分子免疫学杂志,2009,25(2)：133—135.
[24]Zheng W D, Zhang L J, Shi M N, et al. Expression of matrix metal. loproteinase-2 and tissue inhibitor of metal loproteinase—1 in hepatic stellate ceils during rat hepatic fibrosis and its intervention by IL —10[J]. World J Gaatroenterol,2005,11(12):1753-1758
[25]Tomita K, Tamiya G, Ando S, et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non—ahoholic steatohepatitis in mice[J]. Gut, 2006,55:415-24.
[26]Migita K, Maeda Y, Abiru S, et al. Immunosuppressant FKS06 inhibits matrix metalloproteinase-9 induction in TNF-alpha--stimulated human hepatic stellate cells, [J]Sci,2006,78(21):2510-2515
[27]Wan R, wu Y L, Qiao M M, et al. Effect of insulin—like growth factor-1 on hepatic fibrosis in rats[J].% rfd Chin J Digestol, 2005.13(2):211—3.
[28]刘立新,张骞骞,韩德五,等.IGFBP2、IGFBP6在TGF-β1活化的肝星状细胞中表达[J].中国病理生理杂志,2008,24(12)；2481—2483
[29]Vera M, Sobrevals L, Zaratiegui M. et al. Liver transduction with a simian virus 40 vector encoding insulin—like growth factor I reduces hepatic damage and the development of liver cirrhosis [J]. Gene Ther,2007, 14(3):203-10
[30]Tang X, Yang J.Ⅱ J. Sensitization of human hepatic stellate cells to tumor necrosis factor—related apoptosis—inducing ligand— inducedapoptosis by leflunomide[J]. Biol P Bul,2009,32(6):963-967
[31]Son G, Iinmro Y, Seki E, et al. Selective inactivation of NF-kappaB in the liver using NF—kappaB decoy suppresses CC14—induced liver injury and fibrosis[J]. Am J Physiol Gastrointest Liver Physiol, 2007,293(3):G631-9.
[32]Bethanis S K, Theocharis S E. Leptin in the field of hepatic fibro— sis:pivotal or an incidental player, [J]Dig Dis Sei,2006,51 (10):1685-1696.
[33]Honda H, Ikejima K, Yoshikawa M, et al. Leptin is required for fibrogenic responses induced by thioacetamide in the routine liver [J]. Hepatology,2002,36(1):12-21
[34]Nong B, Luo H S, Liang Z W, et al. Relationship between leptin and liver fibrogenesis of rats[J]. Acta Med Sin,2006,19(3):386-388.
[35]Wang J, Leclercq I, Brymora JM, et al. kupffer cells mediate leptin—induced liver fibrosis[J]. Gastroenterology,2009,137(2):713-723.
[36]sj HF.Li J, Lin X, et al. Suppressive effects of leflunomide on leptin-induced collagen I production involved in hepatic stellate cell proliferation[J]. Exp Biol Med,2007,232(3):427-436.
[37]J, Si HF, Lin X, et al. Suppressive effects of leflunomide on leptin--induced TIMP-1 production involves on hepatic stellate cell proliferation and apoptosis[J]. Eur JPharmacol,2008,580(1-2): 63-69.
[38]Radaeva S, Jaruga B, Kim WH, et al. Interferon gamma inhibits interferon alpha signalling in hepatic cells:evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitic C. Biochem J,2004,379:199-208.
[39]Rockey DC, Maher JJ, Jarnagin WR, et. Inhibition of rat hepatic lipocyte activation ineulture by interferon—…. Hepatology,1992, 16(3):776-778.
[40]Tsushima H, Kawata S, Tamara S, et. Reduced plasma transforming growth faetor-betal levels in patients with chronic hepatitis C after in terferon—alpha therapy:Association with regression of hepatic fibros[J]. J Hepatol,1999,30(1):1-7.
[41]Benyon RC, Iredale JP. Is liver fibrosis reversible, Gut 2000:46:443-446
[42]Pinzani M, Marra F, Carloni V. Signal transduction in hepatic stellate cells. Liver 1998:18:2-13
【43]陈平圣,翟为溶,张月娥,张锦生.缺氧对肝星状细胞产生胶原及胶原降解酶影响。世界华人消化杂志2000;8：586-587
[44]白文元,姚希贤,冯丽英.肝纤维化的研究现状.世界华人消化杂志2000;8：1267-1268
[45]Kim KY, Rhim TY, Choi IC, Kim SS. N-Acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity. J Biol Chem 2001; 276:40591-40598
[46]Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000:275:2247-2250
[47]Svegliati-Baroni G, Ridolfi F, Di Sario Benedetti A, et al. Intracellular signaling pathways involved in acetaldehyde-induced collagen and fibronectin gene expression in human hepatic stellate cells. Hepatology 2001:33:1130-1140
[48]Schnabl B, Kweon Y0, Frederick JP, et al. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 2001:34:89-100
[49]甘新宇,蒋明德PDGF与HSC中信号传导关系的研究进展.西南国防医药2000；10：246
[50]Robino G, Parola M, Marra F, Caligiuri A, et al. Interaction between 4-hydroxy-2,3-alkenals and the platelet derived growth factor-beta receptor. Reduced tyrosine phosphorylation and downstream signaling in hepatic stellate cells. J Biol Chem 2000;275:40561-40567
[51]Shimohashi N, Nakamuta M, Uchimura K, et al.. Selenoorganic compound, ebselen, inhibits nitric oxide and tumor necrosis factor-alpha production by the modulation of jun-N-terminal kinase and the NF-kappab signaling pathway in rat Kupffer cells. J Cell Biochem 2000;78:595-606
[52]DerynckR, ZhangYE. Smad dependent and Smad-independent pathways In TGF-Beta familysignaling [J]. Nature,2003,425(6958):577-584
[53]ShiY, MassagueJ. Mechanisms ofTGF-beta signaling from cell membranetothenucleus[J]. Cell,2003,113:685-700
[54]杨小艳,杨勇,郑勇,等.外源Smad7转染肝星状细胞及对转化生长因子B1和Ⅰ、Ⅲ型胶原mRNA表达的影响[J].中国组织工程研究与临床康复,2009,13(50)：9887-9891
[55]NagarajanRP, ChenF, LiW, et al. Repression of transforming growth factor beta mediated transcription by nuclear factor kappaB. [J]. Biochem J,2000,348:591-596.
[56]Bitzer Mvon, LiangD, etal. A mechanism of suppression of TGFbeta/SMAD signaling by NF-kappaB/Re1A. [J].EP Genes Dev,2000,14:872-971.
[57]袁丽萍,陈飞虎,鹿玲,等.鬼针草总黄酮对肝纤维化大鼠肝星状细胞TGF-β1信号传导通路的影响[J].中国药理学通报,2009,25(12)：1655-1659
[58]S Dooley, J Hamzavi, K Breitkopf, et al. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. [J] Gastroenterology, 2003,125(1):178-191
[59]Cano E, Mahadevan LC. Parallel signal processing among mammalian MAPKs. TIBS 1995;20:117-122
[60]Seger R, Krebs EG. The MAPK signaling casade. FASEB J 1995:9:726
[61]Shapiro PS, Ahn NG. Feedback regulation of raf-1 andmitogenactivated protein kinase (MAP) kinase kinases 1 and 2 by MAP kinase phosphatase-1 (MKP-1). J Bio Chem 1998:273:1788-1793
[62]Davis RJ. The mitrogen-activated protein kinase signal transduction pathway. J Biol Chem 1993;268:14553-14556
[63]Page G, Guerin S, Grall D, Bonino F, et al. Defective thymocyte maturation in P44 MAP kinase (Erkl) knock out mice. Science 1999;286:1374-1377
[64]New L, Jiang Y, Zhao M, et al. PRAK, a novel protein kinase regulated by the P38 MAP kinase. EMBO J 1998:17:3372-3384
【65】刘景生.细胞信息与调控.第1版.北京：北京医科大学中国协和医科大学联合出版社,1998：272
[66]Tanoue T, Moriguchi T, Nishida E. Molecular cloning and characterization of a novel dual specificity phosphatase, MKP-5. J Biol Chem 1999:274:19949-19956
[67]Friedman SL. The cellular basis of hepatic fibrosis-mechanisms and treatment strategies. N Engl J Med 1993:328:1828-1835
[68]Aronheim A, Engelberg D, Li N, et al. Membrane targeting of the nucleotide exchange factor sos is sufficient for activating the ras signaling pathway. Cell 1994;78:949-961
[69]Rosen LB, Greenberg ME. Stimulation of growth factor receptor singal transduction by activation of voltage-sensitive calcium channels. Proc Natl Acad Sci USA 1996;93:1113-1118
[70]Farnsworth CL, Freshney NW, Rosen LB, Ghosh A, Greenberg ME, Feig LA. Calcium activation of ras mediated by neuronal exchange factor ras-GRF. Nature 1995;376:525-527
[71]Berra E, Diaz-Meco MT, Lozano J, Frutos S, Municio MM, Sanchez P, Sanz L, Moscat J. Evidence for a role of MEK and MAPK during signal transduction by protein kinase C zeta. EMBO J 1995:14:6157-6163
[72]JF, Petersen DR. Involvement of phosphatidy insitol kinase and extracellular_regulated kinase in hepatic stellate cell an tioxidan tresponse and mvofibroblastic transdifferentiation [J]. Arch Biochem Biophys 2006,446:111-118
[73]Zhou Y, Zheng S, Lin J, et al. The interruption of the PDGF and EGF signaling pathways by curcumin stimulates gene expression of PPAR gamma in rat activated hepatic stellate cell invitro[J], Lab Invest, 2007,87(5):488-498
[74]朱婉凌,马希涛,王思勤PI3K、α—SMA蛋白在特发性肺纤维化肺组织的表达及意义,中国实用医刊,2008,35(12)：27-29
[75]JRoberts R, James N, Cosulich S, etal. The role of protein kinase B and mitogen-activated protein kinase in epidermal growth factor and tumor necrosis factor—a mediated rat hepatocyte survival and apoptosis. Hepatoloy,2000,31:420-427
[76]姚鹏,杨晓明,胡大荣,PI3K/AKT途径在HGF介导肝干细胞抗凋亡调控中的作用,中华微生物和免疫学杂志,2005,25(2)；89-93
[77]刘剑毅,李世荣,PI3K/PKB信号通路参与结缔组织生长因子促人增生性瘢痕纤维化,重庆医学,2008,37(9)：920-923
【78]陈勇,PI3K在T淋巴细胞活化与细胞毒效应中的作用,国外医学免疫学分册,2002,25(3);154-155
【79]刘瑾,施珊娜,许淑云,等.PI3K在细胞外基质分泌细胞因子表达中的作用,中华微生物学和免疫学杂志,2009,29(7)：597-601
[80]Rane MJ。Coxon PY, Powell DW, et al. p38 KiFlaae dependent MAPKAPK 2 activation functions as 3 phosph。inOsitide-dependent kinase—2 for Akt in human neutrophils. J Biol Chem,2001.276 (5):3517-3523.
[81]Steelman LS,. Pohnert S [:, Shelton JG,1} 11. JAK/STAT. RM/ MEK/ERK, PI3K/Akt and BCR ABI in cell cycle progression and leukemogenesis. Leukemia,2004,18(2):189 218
[82]Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt(protein kinase B), Science,1999,286(5445):1741-1744.
[83]Guan KI, Figueroa C, Brtva TR. et al. Negative regulation of these serine /threonine kinase 13-Raf by Akt, J Biol Chem,2000,275(35):27354-27359.
[84]何益,熊伍军,刘菲.Wnt信号转导通路与肝纤维化,[J].国际消化病杂志,2008,28(1)：57--59
[85]Veeman MT, Axelrod JD, Moon RT. A second canon:Functions and mechanisms of beta-catenin independent Wnt signaling, [J]. Dev Cell,2003,5(3): 367-77
[86]Jiang F, Parsons CJ, Stefanovie B. Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation, [J]. Hepatol,2006,45(3):401-409.
[87]Colston JT, dela Rosa SD, Koehler M, et al. Wnt-induced secreted protein-1 is a prohypertrophic and profibrotic growth factor[J]. Am J Physiol Heart Cire Physiol,2007,293(3):H1839-1846.
[88]Bayle J, Fitch J, Jacobsen K, et al. Increased expression of Wnt2 and SFRP4 in Tsk mouse skin:role of Wnt signaling inaltered dermal fibrillin deposition and systemic sclerosis[J]. J Invest Dernmtol, 2008,128(4):871-881.
[89]Sato M. Up regulation of the Wnt/beta—catenin pathway induced by transforming growth factor—beta in hypertrophic scars and keloids [J]. Acta Dern Venereol,2006,86(4):300-307.
[90]Zeng G, Awan F, Otruba W, et al. Wnt'er in liver:expression of wnt and frizzled genes in mouse [J]. Hepatology,2007,45 (1):195-204
[91]Wells RG, Fibrogenesis. V. TGF—beta signaling pathways. Am, Phvsiof Gastrointest Liver Phvsiof 2000:279:G845-G850
【92]孙利兵,王尉平,顾振纶,等.Wnt信号转导通路与肝纤维化[J].中国药理学通报,2008,24(7)；861—864
[93]De Bleser PJ Niki T|Xu G|Rogiers V|Geerts A. Localization and cellular sources of activins innormal and fibrotic rat liver. HepatoloRy 199 26: 905-912
[94]Kiyici M, Gurel S, Budak F, et al. Fas antigen(CD95)expression and apoptosis in hepatocytes of patients with chronic viral hepatitis. Eur J 17Gastroenterol Hepa tol,2003,15:1079-1084,
[95]Murota M, Watanabe S, Fujita J, et al. Aberrant cytokeratin expression and hight susceptibility to apoptosis in autoimmune hepatitis, s. Hepatol Res,2003.25:271-280.
[96]Takehara T, Tatsumi T, Suzuki T, et al. Hepatocyte-speciilc disruption of Bcl—XL leads to continuous hepatocyte apoptosis an d liver fibrotic responses Gastroenterology,2004,127:1189-1197.
[97]Fadok VA, de Cathelineau A, DMeke DL, et al. Loss of phospholipid asymmetry and surface exposure of phosphatidylsefine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J Biol Chem,2001,276:1071-1077.
[98]Canbay A, Taimr P, Torok N, et al. Apoptofic body engulfment by a human stelate eel line is profibrogenic. Lab Invest,2003,83:655-663.
[99]Wielockx B, Larmoy K, Shapiro SD, et al. Inhibition of matrix metalloproteinases blocks lethal hepatitis an d apoptosis induced by tumor necrosis factor an d allows safe anti-tumor therapy. Nat Med, 2001,7:1202-1308
[101]陈旭军.肝纤维化动物模型的选择及评价,[J],湖南中医药导报,2002,8(12) 785
【102】曾林,王慧芳,肝纤维化动物模型的研究概况,[J]中国医学杂志,2003,13(2)：124
【103】黄志刚,程为溶,张月娥等,异种动物血清诱导的大鼠肝纤维化模型及其机制,[J]上海医科大学学报,1997,24(5)；351
【104】刘秀英,胡怡秀,胡余明等,大鼠四氯化碳和猪血清肝纤维化模型比较,[J],世界华人消化杂志,200210(8)；975-978
[105]kobayashi S, Seki S, Kawada N, et al. Apotosis of T cells in the hepatic fibrotic tissue of the rat:apossible inducing role of hepatic myofiborblast-like cells [J]. Cell tissue Res,2003,311(3):353-364
[106]Nan JX, Park E, Lee SH, et al. Antifibrotic effect of stephania tetrandra on experimental liver fibrosis induced by bile duct ligation and scission in rats [J], Arch Pharm Res,2000,23(5):501-506
【107】尹珊珊,王宝恩,王泰龄等,胆管阻塞性肝纤维化亚模型的建立与改进,【J】中华肝病杂志,2002,10(5)：385-386
【108】陈秀英,季晖,张奕华,等.一氧化氮供体型齐墩果酸衍生物ZCⅡ2对早期实验性肝纤维化的保护作用,中国临床药理和治疗学,2005；10(11)：1261—1265
[109]Hamada H, Yatsuhashl H, Yano K, et al. Interleukin—10 promoter polymorpbiSInS and liver fibrosis progression in patients with chronic hepatitis C in Japan. J Hepatol.2003; 39(3):457-458
[110]Nelson DR, Tu Z, Soldevila Pico C, et al. Long term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti—inflammatory effect. Hepatology.2003; 38(4):859-868
[111]Barth H, Klein R, Berg PA, et al. Analysis of the effect of IL—10 therapy on immunoregulatory T—cell subsets in patients with chroniC hepatitis C infection. Hepatogastroenterology.2003; 50(49):201-206.
【112】谢娟,张惠娜,黄能慧,李诚秀,秋水仙碱对免疫性肝纤维化的防治作用贵州医药,2002,26(10)：885-887
【113】吕霞,舒建昌,何雅军,秋水仙碱抑制肝星状细胞活化与抗肝纤维化的作用,广东医学,2006,27(12)：1796-1798
[114]Luckey Sw, peterson DR, Activation of kuppfer cells during the course of carbon tetrachloride induced liver injury and fibrosis in mice[J]exp mol pathol,2001,71(3):226-228
【115】陆伦根.肝纤维化的药物治疗.药品评价,2006,3(5)：339-340
【116】江余勤,程五风,李宣海.维生素E与肝纤维化.临床肝胆病杂志,2000,16(1)： 19
[117]Guo JS, Wang JY, Liu WT, et al. Effects of potenlini and IFN-α on mRNA expression of procollagen type Ⅰ, Ⅲ and collagenase in liver and hepatic fibrosis model, Gut,1997,41(13):A178-180
[118]苌新明,常英,干扰素对实验大鼠肝内纤维组织及肝星状细胞的影响,肝脏,2004,9(13)：171-173
[119]Watnabe T, Nioka A, Hozawa S, et al. Dynamic of cell s expressing MMP-2 mR.NA and MTi-MMP mRNA in the recoverv from liver fibrosis in the rat. J Hepatol,2001,35:465-473
[120]BARONI GS, D'AMBROSIO L, CURTO P, et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis[J]. Hepatology,1996,23:1189-1199
[121]ROCKEY DC. Antiftbrotic therapy in chronic liver disease[J]. Clin Gastroenterol Hepatd,2005,3(2):95-100
[122]WENG HL, CAI WM, LIU RH. Animal experiment and clinical study of effect of gamma-interferon on hepatic fibrosis[J]. World J Gastroenterology, 2001,7(1):42-44
[123]WENG H, MERTENS PR, GRESSNER AM, et al. IFN-gamma abrogates profibrogenic TGF-beta signaling in liver by targeting expression of inhibkory and receptor Smads [J]. J Hepatol,2007,46(2):295-303
[124]WANG L, WANG BE, WANG J, et al. Herbal compound 861 regulates mRNA expression of collagen synthesis.2005,12; 144-147
[125]Ruwart MJ, Henley KS. Prostaglandins in liver disease and liver transplantation. Gastroenterol Clin North Am.1996 Jun;25(2):397-407.
[126]Lim DS, lutucuta S, Bachireddy P, et al. Angiotensin Ⅱ blockade reverse mycocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomycopathy, [J] circulation,2001,103(6);789-791
[127]胡咏武,王胜春,李哲,等.丹参酮Ⅱ A对LPs等诱导的肝细胞损伤及枯否细胞释放细胞因子的作用[J].中国药理学通报,2005,21(12)：1482—1486
[128]刘成海,刘平,胡义扬,等.丹酚酸B盐对转化生长因子—β 1刺激肝星状细胞活化与胞内信号转导的作用[J].中华医学杂志,2002,82(18)：1267—1272
[129]赖文芳,吴符火,陈兴明.丹参抗肝纤维化作用机制的研究进展,中国民族民间医药2010,2：31-33
[130]郭伟强,陈曦,曹婷婷等,丹参酮Ⅱ—A对抗炎症因子Ⅱ—10的调节作用时效关系[J].中国药理学通报,2009,25(5)：697—680
【131]王要军,孙自勤,权启镇等.汉房己甲素治疗大鼠实验性肝纤维化的研究.临床肝胆病杂志,1993,9(3)：40—41
[132】王继明,倪世秋.络病用药规律处探.中国中医基础医学杂志,2001,7(3)：56-58
[133]杨文卓,曾民德,范竹萍,等.氧化苦参碱防治二甲基硝胺诱导的大鼠肝纤维化的实验研究[J].中华消化杂志,2003,23(3)：165—168.
[134]余小虎,朱金水,朱祖明,等.氧化苦参碱对肝纤维化大鼠肝组织TGF-β1与TNF-α表达的影响[J].肝脏,2004,9(4)：254—255
[135]谈博,宋健平,张奉学,等.川芎嗪对HSC-T6细胞Smad蛋白细胞内转位的影响[J].中药新药与临床药理,2006,17(5)：320—322.
[136]董玲,孙剑勇,方国汀,等.甘草酸对转化生长因子β刺激肝星状细胞信号传导的作用[J].中华肝脏病杂志,2005,13(11)：828—831.
[137]谢明,廖晓宏,杨元胜,等.姜黄素对肝星状细胞株CTGF表达的影响[J].实用医学杂志,2006,22(15)：1724—172
[138]肖东征,高艽,马宁.水飞蓟磷脂复合物对化学性肝损伤的保护作用[J].中国自然医学杂志,2005,7(3)：205—207
[139]王字,贾继东.水飞蓟的抗肝纤维化作用及其机制[J].中华医学杂志,2005,85(17)：1219—1221
[140]王占海,沈凌鸿,陈向东,等.水飞蓟素对脂多糖大鼠急性肺损伤的拮抗作用[J].中国病理生理学杂志,2007,23(2)：280-283
[141】邢凌翔,贺永文.水飞蓟素对大鼠非酒精性脂脉性肝炎的防治作用及机制[J].胃肠病学和肝病杂志,2007,16(1)：60-62
[142]王宇,贾继东,杨寄华,等.水飞蓟素对实验性肝纤维化大鼠的疗效及其作用机制的研究[J].国外医学.消化系疾病分册,2005,25(4)：256-259
[143]刘平,方步武,刘成,等.转化生长因子β1及虫草多糖对大鼠肝纤维化形成的影响.中华肝脏病杂志1998；6(4)：232
[144]方步武,刘平,刘成,等.虫草多糖抗免疫损伤性大鼠肝纤维化的作用及其机理研究.上海中医药杂志2000；34(9)：37-38
[145]Shimim I. Sho-saiko-to:Japanese herbal medicine for protection nst hepatlcfibrosis and eareinonm. J Gastorenterol Hepatol,2000,15:D84
[146]尤红,王宝恩,王泰龄,等.复方861对肝星状细胞的增殖和凋亡的干预作用.中华肝脏病杂志,2010,8(2)：78—80
[147]王宝恩.肝纤维化及肝硬变的可逆性.中西医结合肝病杂志,2000,(S1)：2241
[148]姜春萌,刘成海,刘成.扶正化瘀胶囊对肝星状细胞激活的干预.中国中西 医结合消化杂志,2003；11(5)：280
[149]蔺武,刘心娟.复方鳖甲软肝片抗肝纤维化疗效的系统评价.胃肠病学和肝病学杂志,2007,16(1)：69—71
[150]宣红萍,孙保木,陶艳艳,等.扶正化瘀方对大鼠脂肪性肝炎与肝纤维化的作用[J].药品评价,2007,4(6)：414-418
[151]张琪,田字彬.小柴胡汤对实验性肝纤维化模型大鼠肝组织中Ⅰ、Ⅲ型胶原表达干预研究[J].山东中医药大学学报,2005,45(4)：316—318
[152]周小舟,周大桥.中药软肝冲剂对肝纤维化大鼠p21细胞周期调控的影响[J].中国中西医结合消化杂志,2003,11(5)：267-269
[153]都广礼,郑洪新,刘学文,等.免疫性肝纤维化大鼠脾脏淋巴细胞产生IL-2和IFN—Y的变化及疏肝利胆方药物血清对其影响[J].中医药学刊,2005,23(1)：75—76
[154]张俊杰,黄亚鹏,李寿生等, 桃核参术汤对大鼠肝纤维化形成过程中Ang Ⅱ 1型受体mRNA表达的影响,世界中西医结合杂志,2010,5(7)；586-587
[155]姜春萌,刘成,刘平.肝纤维化过程中肝星状细胞研究进展[J].中华消化杂志,2000,20(4)：30-32
[156】薛博瑜,清化瘀毒法治疗肝纤维化的体会【J】.江苏中医药,2007,39(5)；63-65
【157]杨培明聂广,重型肝炎的诊断与治疗,中西医结合肝病杂志,1998,8(4)；195-197
【158]齐洪军,胡曼菁,祛瘀化痰汤对肝纤维化大鼠肝组织α-平滑肌肌动蛋白表达、分布的影响的实验研究,青海医药杂志,2004,34(5)：14-17
【159]卢良威,陈群伟,蔡卫民等,肝纤维化大鼠Bcl—2、Bax的表达及活血渗湿方对其的作用,浙江中医学院学报,2003,3(27)；51-53
[160]杨倩,胡冬菊,冯玉彦等,姚希贤教授中西医结合治疗慢性肝炎肝纤维化经验,【J】陕西中医,2007,28(9)：1209—1211
[161】朱建明.“活血软坚合剂”对肝纤维化血清指标的影响.江苏中医药2006;27：27-28
[162]张斌,王灵台,陈建杰,王中华,赵莹.虎杖清肝汤治疗慢性乙型肝炎及对肝纤维化形成的影响.上海中医药大学学报2007：21：37-39
[163]孙劲晖,调肝理脾方治疗酒精性肝纤维化,医药信息,2002,19(2)：45
[164]吴秀美,刘友章,软肝抗纤方治疗肝纤维化41例疗效观察,新中医,2003,35(3)：29-31
[165]李志伟,程良斌,抗纤软肝颗粒对大鼠肝星状细胞增殖的影响,中西医结合肝病杂志,2010,20(2)：95-97
[166]刘益平,软肝抗纤方对肝纤维化实验大鼠TGF-1/Smad信号转导通路的影响,中国医药指南,2010,第8卷,1650-1652
[167]刘天虹,健脾软肝方抗肝纤维化的临床观察,广西中医学院学报,2005,8(2);7
[168]薛霁,郑万平,徐丹,健脾软肝煎治疗乙肝肝纤维化(肝郁脾虚证)30例疗效观察,新中医,2005,37(12)；44-46
[169]陈文慧,唐阁,马洁,福尔肝健脾软肝方及拆方对GEl4肝纤维化大鼠脂质过氧化的影响,云南中医学院学报,2007,30(4)；34-37
[170]陈文慧,魏东,马洁,等,福尔肝健脾软肝方及拆方对GEl4肝纤维化大鼠MMP—2、MMP—9活性及蛋白表达的影响,云南中医学院学报,2007,30(1)；29-32
[171]陈文慧,魏东,唐阁,福尔肝健脾软肝方及拆方对CCI4肝纤维化大鼠肝功能的影响,云南中医学院学报,2006,29(4)；13-16
[172]雷力民,田玉玲,邓洪彪,升肝健脾颗粒对肝纤维化大鼠肝脏细胞因子含量的影响,广西南宁辽宁中医药大学学报,2008,10(10)；153